source
- Psychedelic therapeutics near first FDA approval as Compass Pathways and Definium report promising resultsBioSpace notes that the psychedelic drug sector is regaining momentum after a setback in 2024 when Lykos’ MDMA therapy failed to win FDA clearance. The focus has shifted to new candidates, with Com…
- FDA holds psychedelic forum as Definium reports third successful Phase 3 trial of oral LSD for anxietyThe FDA convened a public forum on Monday to discuss the near‑term outlook for psychedelic drug development, highlighting interest from companies such as Compass Pathways and Definium Therapeutics.…